Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis

被引:26
|
作者
Strand, Vibeke [1 ]
Tundia, Namita [2 ]
Song, Yan [3 ]
Macaulay, Dendy [3 ]
Fuldeore, Mahesh [2 ]
机构
[1] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA
[2] AbbVie, N Chicago, IL USA
[3] Anal Grp, Boston, MA USA
来源
关键词
METHOTREXATE THERAPY; CONTROLLED-TRIAL; DOUBLE-BLIND; TOCILIZUMAB; COMBINATION; ETANERCEPT; PREVALENCE; INFLIXIMAB; ADALIMUMAB; INHIBITOR;
D O I
10.18553/jmcp.2018.24.4.344
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Targeted immunomodulators (TIMs), including biologic disease-modifying antirheumatic drugs (DMARDs) and JAK/STAT inhibitors, are effective therapies for rheumatoid arthritis (RA), but some patients fail to respond or lose response over time. This study estimated the real-world prevalence of RA patients with inadequate responses to an initial TIM (nonresponders) in the United States and assessed their direct and indirect economic burden compared with treatment responders. METHODS: Administrative claims data (January 1999-March 2014) from a large private-insurer database were used, which included work-loss data from a subset of reporting companies. Eligible patients (classified as responders and nonresponders) had >= 1 claim for a TIM approved for the treatment of RA and >= 2 RA diagnoses in the claims history, with continuous pharmaceutical and medical benefit eligibility for 6 months before (baseline) and 12 months after (study period) the date of the first TIM claim (index date). All-cause and RA-related health care resource use (HCRU) and costs, work loss, and indirect costs during the study period were compared for responders versus nonresponders. Multivariable regression was used to adjust for baseline covariates. Sensitivity analyses of HCRU and direct costs were conducted for patients with index dates before and after 2008 to account for different approval dates of TIMs. RESULTS: Of 7,540 eligible patients with RA, 2,527 (34%) were classified as responders, and 5,013 (66%) were classified as nonresponders; 407 and 723 had work-loss data, respectively. After adjusting for baseline covariates, nonresponders had significantly higher HCRU, including inpatient admissions (incidence rate ratio [IRR] = 1.94), outpatient visits (IRR = 1.19), emergency department visits (IRR = 1.53), and number of prescription fills (IRR = 1.09; all, P < 0.001). Nonresponders also had significantly higher adjusted all-cause ($12,868 vs. $9,621, respectively) and RA-related ($5,740 vs. $4,495; both, P < 0.001) medical costs compared with responders. In addition, nonresponders reported significantly more days of work lost compared with responders (22.1 vs. 16.7 days, respectively; IRR = 1.21; P = 0.007) and higher indirect costs ($3,548 vs. $2,890; P = 0.002). Sensitivity analyses of HCRU and direct costs by index date (before and after 2008) were consistent with the full sample. CONCLUSIONS: A large portion of patients with RA had inadequate responses to their initial TIM therapy with significantly higher economic burden, including higher HCRU, medical costs, and indirect costs due to work loss, compared with TIM therapy responders. Copyright (C) 2018, Academy of Managed Care Pharmacy. All rights reserved.
引用
收藏
页码:344 / 352
页数:9
相关论文
共 50 条
  • [31] Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab
    Ornetti, P
    Solau, E
    Gaudin, P
    Sibilia, J
    Berthelot, JM
    Puechal, X
    Tavernier, C
    Maillefert, JF
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (09) : 1379 - 1380
  • [32] EFFICACY OF UPADACITINIB IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO FIRST GENERATION JAK INHIBITORS
    Kamiya, M.
    Mori, S.
    Yamazaki, K.
    Togawa, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83
  • [33] Cost-effectiveness of treatment strategies for rheumatoid arthritis patients with inadequate response to methotrexate
    Patel, VD
    Hay, J
    VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [34] Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
    Emery, Paul
    RHEUMATOLOGY, 2012, 51 : V22 - V30
  • [35] Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Prior Therapies
    Tesser, John
    Gul, Ahmet
    Olech, Ewa
    Oelke, Kurt
    Lukic, Tatjana
    Murray, Christopher W.
    Zang, Chuanbo
    Takiya, Liza
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [36] PREDICTORS OF PROGRESSION TO ADVANCED THERAPY AMONG RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE ON CDMARDS
    Grabner, M.
    Boytsov, N.
    Zhang, X.
    Raval, A.
    Curtis, J. R.
    VALUE IN HEALTH, 2017, 20 (05) : A6 - A7
  • [37] Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
    Buch, Maya H.
    Walker, David
    Edwards, Christopher J.
    Barry, Jane
    Akroyd, Laura
    Omoruyi, Edmund V. Ekoka
    Taylor, Peter C.
    RHEUMATOLOGY, 2024,
  • [38] Do patients with rheumatoid arthritis demonstrate an improvement on etanercept following an inadequate response to infliximab?
    Buch, MH
    Bingham, SJ
    Bejarano, V
    White, J
    Emery, P
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S325 - S325
  • [39] Infiltrations of plasma cells in synovium predict inadequate response to Adalimumab in Rheumatoid Arthritis patients
    Li, Jian Bin
    Liu, Peng Cheng
    Chen, Liming
    Wu, Rui
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [40] SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE
    Fleischmann, Roy
    Meerwein, Sebastian
    Charles-Schoeman, Christina
    Combe, Bernard
    Hall, Stephen
    Khan, Nasser
    Carter, Kyle
    Camp, Heidi
    Rubbert-Roth, Andrea
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 43 - 43